PDCD1 and cancer: Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) or its ligand (PD-L1), have elicited unprecedented long-term disease remissions in advanced and previously treatment-refractory cancers [1,2,3].